Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-12-18
2011-12-27
David, Zinna Northington (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S146000
Reexamination Certificate
active
08084464
ABSTRACT:
This invention relates to novel tetrahydroisoquinoline derivatives, their derivatives, pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a dual OX-1/OX-2 orexin antagonist.
REFERENCES:
patent: 6221335 (2001-04-01), Foster
patent: 6440710 (2002-08-01), Keinan et al.
patent: 6603008 (2003-08-01), Ando et al.
patent: 6916830 (2005-07-01), Lee et al.
patent: 7517990 (2009-04-01), Ito et al.
patent: 2007/0082929 (2007-04-01), Gant et al.
patent: 2007/0197695 (2007-08-01), Potyen et al.
patent: 2008/0103122 (2008-05-01), Veltri
patent: WO 95/26325 (1995-10-01), None
patent: WO 2005118548 (2005-12-01), None
patent: WO 2007/105177 (2007-09-01), None
patent: WO 2007/118651 (2007-10-01), None
patent: WO 2009/079637 (2009-06-01), None
Written Opinion of PCT/US08/87477 (Form 237), completed Feb. 2008.
Bailie, T. A., “The Use of Stable Isotopes in Pharmacological Research,”Pharmacological Reviews, 33(2): 81-132 (1981).
Brisbare-Roch, C., et al., “Promotion of Sleep by Targeting the Orexin System in Rats, Dogs and Humans,”Nature Medicine, 13(2), 150-155 (2007).
Browne, T. R., “Stable Isotope Techniques in Early Drug Development: An Economic Evaluation,”J. Clin. Pharmacol., 38: 213-220 (1998).
Cherrah, Y., et al., “Study of Deuterium Isotope Effects on Protein Binding by Gas Chromatography/Mass Spectrometry. Caffeine and Deuterated Isotopomers,”Biomedical and Environmental Mass Spectrometry, 14: 653-657 (1987).
Dyck, L. E., et al., “Effects of Deuterium Substitution on the Catabolism of β-Phenylethylamine: An In Vivo Study,”Journal of Neurochemistry, 46(2): 399-404 (1986).
Fisher, M.B. et al., “The Complexities Inherent in Attempts to Decrease Drug Clearance by Blocking Sites of CYP-Mediated Metabolism,”Curr. Opin. Drug Discov. Devel., 9(1):101-109 (2006).
Foster, A. B., “Deuterium Isotope Effects in Studies of Drug Metabolism,”Trends in Pharmacological Sciences, 5: 524-527 (1984).
Foster, A. B., “Deuterium Isotope Effects in the Metabolism of Drugs and Xenobiotics: Implications for Drug Design,”Advances in Drug Research, 14: 1-40 (1985).
Gouyette, A., “Synthesis of Deuterium-labelled Elliptinium and its Use in Metabolic Studies,”Biomedical and Environmental Mass Spectrometry, 15: 243-247 (1988).
Haskins, N. J., “The Application of Stable Isotopes in Biomedical Research,”Biomedical Mass Spectrometry, 9(7): 269-277 (1982).
Honma S., et al., “The Metabolism of Roxatidine Acetate Hydrochloride,”Drug Metabolism and Disposition, 15(4): 551-559 (1987).
Kushner, D.J. et al., “Pharmacological Uses and Perspectives of Heavy Water and Deuterated Compounds,”Can. J. Physiol. Pharmacol., 77:79-88 (1999).
Pieniaszek, H. J., et al., “Moricizine Bioavailability via Simultaneous, Dual, Stable Isotope Administration: Bioequivalence Implications,”J. Clin. Pharmacol, 39: 817-825 (1999).
Tonn G. R., et al., “Simultaneous Analysis of Diphenhydramine and a Stable Isotope Analog (2H10) Diphenhydramine Using Capillary Gas Chromatography with Mass Selective Detection in Biological Fluids from Chronically Instrumented Pregnant Ewes,”Biological Mass Spectrometry, 22: 633-642 (1993).
Wolen, R. L., “The Application of Stable Isotopes to Studies of Drug Bioavailability and Bioequivalence,”J. Clin. Pharmacol., 26: 419-424 (1986).
Notification of Transmittal of the International Search Report (ISR) and the Written Opinion (WO) of the International Searching Authority, or the Declaration; International Application No. PCT/US08/087477, Date of Mailing Feb. 25, 2009.
Notification Concerning Transmittal of International Preliminary Report on Patentability, International Application No. PCT/US2008/087477, Date of Mailing Jul. 1, 2010.
CoNCERT Pharmaceuticals, Inc.
David Zinna Northington
Hamilton Brook Smith & Reynolds P.C.
LandOfFree
Tetrahydroisoquinoline derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tetrahydroisoquinoline derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetrahydroisoquinoline derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4269402